Group 1 - The core point of the article is the approval of the上市申请 for Visepegenatide, a chemical raw material drug, by the National Medical Products Administration, which reflects the company's comprehensive strength in R&D, production, and quality management [1][3] Group 2 - Visepegenatide is a PEGylated form of Exenatide that acts as a GLP-1 receptor agonist, mimicking the physiological effects of natural GLP-1, enhancing insulin secretion, and lowering blood glucose levels in a glucose-dependent manner, thus treating type 2 diabetes and obesity [2] Group 3 - The approval of Visepegenatide's上市申请 is expected to positively impact the company's operational development and accumulate valuable experience for future drug research [3]

Group 1 - The China Vaccine Industry Association has issued an initiative to prohibit bidding below cost, aiming to combat "involution" competition and ensure product and service quality standards in the vaccine industry [1] - The initiative is expected to improve the industry ecosystem and create a fair and orderly competitive environment [1] Group 2 - Bailitianheng has signed a strategic cooperation agreement with the Bank of China Sichuan Branch, which promises to provide comprehensive credit support of no less than 8 billion RMB over five years [2] - This large credit line is expected to alleviate the company's short-term financial pressure from high R&D expenditures and reflects the financial institution's recognition of its industry position and business prospects [2] Group 3 - Haizheng Pharmaceutical's subsidiary plans to invest 100 million RMB in a pet prescription food project, aiming for an annual production capacity of 10,000 tons upon reaching full capacity [3] - The company's diversification strategy includes investments in pet nutrition and synthetic biology, though the conversion to revenue growth remains to be seen [3] Group 4 - Saintno Biological has received a marketing approval notification for the raw material drug Weipena peptide, which is used to treat type 2 diabetes and obesity [4] - This approval reflects the company's comprehensive strength in R&D, production, and quality management, positively impacting its business development [4] - The approval comes amid the expansion of the GLP-1 market, indicating a positive outlook for the company's future growth [4]

Group 1 - The core announcement is that Chengdu Santuo Biotech Co., Ltd. has received the approval notice for the listing application of the active pharmaceutical ingredient Visepegenatide from the National Medical Products Administration [1][2] - Visepegenatide is a PEGylated form of exenatide that acts as a GLP-1 receptor agonist, mimicking the physiological effects of natural GLP-1, enhancing insulin secretion, and lowering blood glucose levels in a glucose-dependent manner, thus treating type 2 diabetes and obesity [2][3] - The approval of Visepegenatide is a reflection of the company's comprehensive strengths in research, production, and quality management systems, which will contribute positively to the company's future drug research and overall business development [3]

Group 1 - Kanglongda's shareholder plans to reduce holdings by up to 3% of the company's shares, totaling no more than 4.83 million shares [1] - The company specializes in the research, production, and sales of special and ordinary labor protection gloves [1] Group 2 - Haizheng Pharmaceutical's subsidiary plans to collaborate with East China Institute on a biological method for synthesizing heparin, with a project contract amount not exceeding 120 million yuan [2] - The company focuses on the research, production, and sales of chemical raw materials and formulations [3] Group 3 - Tianyin Holdings received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [4] - The company is engaged in the sales of smart terminals, e-commerce, lottery, mobile resale, and mobile internet businesses [4] Group 4 - Shanghai Yashi plans to use up to 200 million yuan of temporarily idle raised funds for cash management in high-security, liquid deposit products [5] - The company specializes in supply chain logistics and execution trade [6] Group 5 - Parker New Materials intends to use 130 million yuan of idle raised funds to purchase structured deposits with expected annual yields between 0.59% and 2.9001% [7] - The company focuses on the research, production, and sales of various types of ring forgings, free forgings, and die forgings [7] Group 6 - Huayang New Materials appointed Jing Hongsheng as the new general manager [8] Group 7 - Liyuan Technology's shareholder plans to reduce holdings by up to 2.03% of the company's shares, totaling no more than 3.04 million shares [9] - The company specializes in the research, design, and integration of environmental water treatment systems and hydrogen fuel cell engine systems [9] Group 8 - Shengnuo Biopharmaceutical's subsidiary received approval for the listing application of Visepegenatide raw materials, a GLP-1 receptor agonist for treating type 2 diabetes and obesity [10][11] - The company focuses on the research, production, and sales of peptide raw materials and formulations [10] Group 9 - Puluo Pharmaceutical plans to repurchase shares worth between 180 million and 360 million yuan, with a maximum price of 23 yuan per share [12] - The company specializes in the research, production, and sales of raw material intermediates and innovative drugs [12] Group 10 - Dongfang Electric's subsidiary plans to establish a joint venture with Anhui Waneng Energy, with a registered capital of approximately 1.857 billion yuan [13] - The company is involved in the development, design, manufacturing, and sales of advanced power generation equipment [13] Group 11 - Hefei China announced that its stock will resume trading on November 20 after completing a review of abnormal trading fluctuations [14] - The company focuses on international trade and after-sales services related to in vitro diagnostic medical devices [14] Group 12 - Dafeng Industrial won a bid for the stage equipment project of the Shenzhen International Performing Arts Center, with a contract amount of 165 million yuan [15] - The company specializes in cultural sports equipment, digital art technology, and operation services [15] Group 13 - Baiyunshan's subsidiary received a drug registration certificate for An Gong Niu Huang Wan in Vietnam [16] - The company is engaged in the research, manufacturing, and sales of traditional Chinese and Western medicines [16] Group 14 - Neusoft Group received a notification to supply intelligent cockpit domain controllers for multiple models from a well-known domestic automobile manufacturer, with an estimated total amount of about 4.2 billion yuan [17] - The company focuses on providing industry solutions and software products [17] Group 15 - Huayu Pharmaceutical's product received overseas marketing approval [18] - The company specializes in the research, production, and sales of innovative and high-quality generic drugs in the oncology field [18] Group 16 - Yao Pi Glass received approval from the CSRC for its stock issuance to specific investors [19] - The company specializes in the production and sales of float glass and processed glass [19] Group 17 - Guangyu Yuan's vice president Wang Junbo resigned due to work adjustments [20] - The company focuses on the production and sales of traditional Chinese medicine products [20] Group 18 - Biyi Co. received approval from the CSRC for its stock issuance to specific investors [21] - The company specializes in the design, manufacturing, and sales of smart small household appliances [21] Group 19 - Sunshine Nuohe's application for acquiring 100% equity of Jiangsu Langyan Life Science Technology Co., Ltd. through share issuance and convertible bonds has been accepted by the Shanghai Stock Exchange [22] - The company provides comprehensive drug research and development services for domestic pharmaceutical enterprises and research institutions [22] Group 20 - Longxin General plans to increase capital in its wholly-owned subsidiary by no more than 1.65 billion yuan [23] - The company specializes in the research, production, and sales of motorcycles and engines [23] Group 21 - Jiekang Equipment received a corrective order from the Tianjin Securities Regulatory Bureau due to internal control deficiencies [24] - The company specializes in the research, production, and sales of nuclear biochemical safety equipment [24] Group 22 - Wantong Technology plans to raise no more than 920 million yuan through a private placement to supplement working capital [25] - The company focuses on information technology services for highways and ports [25] Group 23 - Dongshan Precision has submitted an application for H-share listing to the Hong Kong Stock Exchange [26] - The company specializes in the research, production, and sales of electronic circuit products and precision components [26] Group 24 - Yonghe Intelligent Control plans to publicly transfer 100% equity of its wholly-owned subsidiary Kunming Medical Oncology Hospital [27] - The company specializes in water and heating valve fittings, tumor precision radiation therapy, and photovoltaic battery businesses [27] Group 25 - Aok Shares signed a strategic cooperation framework agreement with Suzhou Qitian New Materials Co., Ltd. [28] - The company focuses on the research and production of high-end new materials derived from ethylene oxide and ethylene [28] Group 26 - Hongquan Technology's shareholder plans to reduce holdings by up to 3% of the company's shares, totaling no more than 299,440 shares [29] - The company specializes in the research, production, and sales of intelligent connected products and software platform development [29] Group 27 - Shilong Industrial's controlling shareholder plans to reduce holdings by up to 3% of the company's shares, totaling no more than 7.2 million shares [30] - The company specializes in the research, production, and sales of chemical products [30] Group 28 - Tangrenshen decided to terminate the investment in the "Dongchong Phase III Pig Breeding Base Construction Project," reallocating the remaining funds of 78.9587 million yuan to supplement working capital [31] - The company specializes in the research, production, and sales of feed, pigs, meat products, and animal health products [31] Group 29 - Gaode Infrared's actual controller plans to reduce holdings by up to 3% of the company's shares, totaling no more than 12.8 million shares [32] - The company specializes in infrared focal plane detector chips and infrared thermal imaging systems [32] Group 30 - Kangyuan Pharmaceutical's actual controller recently increased holdings by 20,000 shares [33] - The company specializes in the research, production, and sales of pharmaceuticals [33] Group 31 - Haida Group plans to repurchase shares worth between 1 billion and 1.6 billion yuan, with a maximum price of 62.00 yuan per share [34] - The company provides overall solutions for animal husbandry [34] Group 32 - Qizhong Technology's 850 million yuan convertible bonds have been approved for listing [35] - The company specializes in advanced packaging and testing of integrated circuits [35] Group 33 - Dingyang Technology launched the new SNA5000B series vector network analyzer [36] - The company specializes in the research, production, and sales of general electronic testing and measuring instruments [36] Group 34 - Airo Energy plans to distribute a cash dividend of 0.9375 yuan per share to all shareholders [37] - The company specializes in photovoltaic energy storage systems and products [37] Group 35 - Hechuan Technology's actual controller and some directors plan to reduce holdings by up to 6% of the company's shares [38] - The company specializes in the research, production, and sales of industrial automation products [38] Group 36 - China First Heavy Industries' chairman was arrested for suspected bribery [39] - The company specializes in heavy machinery manufacturing for various industries [39] Group 37 - Lianhuan Pharmaceutical plans to invest 15 million yuan in joint research with Nanjing University for anti-thrombotic small nucleic acid drugs [40] - The company specializes in the manufacturing and sales of chemical raw materials [40] Group 38 - Anxu Biotech's shareholder plans to reduce holdings by up to 0.94% of the company's shares, totaling no more than 120,000 shares [41] - The company specializes in the research, production, and sales of POCT reagents and instruments [41] Group 39 - Yaxiang Integration's shareholder reduced holdings by 130,000 shares [42] - The company specializes in providing cleanroom engineering and related services for high-tech electronic industries [42] Group 40 - Zhongwen Media plans to use up to 9.5 billion yuan of idle funds to purchase financial products [43] - The company specializes in traditional publishing and various new media businesses [43]

Core Viewpoint - The announcement from Shengnuo Biopharmaceuticals indicates that its wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the raw material drug, Weipena peptide [2] Group 1 - Shengnuo Biopharmaceuticals has a wholly-owned subsidiary named Chengdu Shengnuo Biopharmaceutical Co., Ltd. [2] - The company has received a marketing approval notification for Weipena peptide raw material from the National Medical Products Administration [2]

Core Viewpoint - Shengnuo Biopharmaceutical has received approval from the National Medical Products Administration for the production of its active pharmaceutical ingredient, Vepagliflozin, which is aimed at treating type 2 diabetes and obesity [1] Company Summary - Shengnuo Biopharmaceutical's wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., has been granted a production approval notice for Vepagliflozin [1] - Vepagliflozin is a PEGylated form of Exenatide that activates GLP-1 receptors in the body, mimicking the physiological effects of natural human GLP-1 [1] Industry Summary - Vepagliflozin functions as a GLP-1 receptor agonist, enhancing insulin secretion in a glucose-dependent manner to lower blood sugar levels [1] - The drug is positioned to address the growing prevalence of type 2 diabetes and obesity, which are significant health concerns globally [1]

Core Viewpoint - The approval of the raw material drug Visepegenatide by the National Medical Products Administration represents a significant milestone for the company, showcasing its comprehensive strengths in research, production, and quality management [1] Group 1: Product Approval - The company’s wholly-owned subsidiary, Chengdu Saintno Biological Pharmaceutical Co., Ltd., has received the approval notice for the listing application of Visepegenatide raw material drug [1] - The registration number for the approval is Y20230000631, and the chemical raw material drug registration standard number is YBY71372025 [1] Group 2: Product Description - Visepegenatide is a polyethylene glycol (PEG) modified exenatide that acts as a GLP-1 receptor agonist, mimicking the physiological effects of natural human GLP-1 [1] - It lowers blood sugar levels by enhancing insulin secretion in a glucose-dependent manner, making it suitable for the treatment of type 2 diabetes and obesity [1] Group 3: Implications for the Company - The approval of Visepegenatide is a testament to the company's capabilities in research and development, production, and quality management systems [1] - This achievement is expected to accumulate valuable experience for the company’s future drug research and has a positive impact on its operational development [1]

证券代码：688117 证券简称：圣诺生物 公告编号：2025-033 包装规格：25g/瓶 申请事项：境内生产化学原料药上市申请 成都圣诺生物科技股份有限公司 关于自愿披露维培那肽原料药获得上市申请 批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都圣诺生物科技股份有限公司（以下简称"公司"）全资子公司成都圣诺 生物制药有限公司于近日收到国家药品监督管理局（以下简称"国家药监局"） 签发的关于维培那肽原料药的《化学原料药上市申请批准通知书》，现将相关情 况公告如下： 一、药品基本情况 登记号：Y20230000631 化学原料药名称：Visepegenatide/维培那肽 化学原料药注册标准编号：YBY71372025 特此公告。 成都圣诺生物科技股份有限公司 董事会 生产企业：成都圣诺生物制药有限公司 审批结论：根据《中华人民共和国药品管理法及有关规定》，经审查，本品 符合药品注册的有关要求，批准本品注册生产。生产工艺、质量标准和包装标签 照所附执行。 二、药品的其他情况 维培那肽，是一种聚乙二醇（ ...

Core Viewpoint - The company, Shengnuo Biopharmaceutical (688117), has received approval from the National Medical Products Administration for the marketing application of its active pharmaceutical ingredient, Vepagliflozin, which is a PEGylated form of Exenatide, aimed at treating type 2 diabetes and obesity [1] Group 1 - Shengnuo Biopharmaceutical's subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., has recently received a marketing approval notification for Vepagliflozin [1] - Vepagliflozin acts as a GLP-1 receptor agonist, mimicking the physiological effects of natural GLP-1 by enhancing insulin secretion in a glucose-dependent manner [1] - The drug is intended for the treatment of type 2 diabetes and obesity, indicating its potential market relevance in addressing these health issues [1]

Core Viewpoint - Shengnuo Biopharmaceutical (688117.SH) announced that its wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., has received the approval notice for the marketing application of the active pharmaceutical ingredient, Vepagliflozin, from the National Medical Products Administration (NMPA) [1] Group 1 - The approved drug, Vepagliflozin, is a polyethylene glycol (PEG) modified version of Exenatide, which acts as a GLP-1 receptor agonist [1] - Vepagliflozin mimics the physiological effects of natural human GLP-1 by enhancing insulin secretion in a glucose-dependent manner, thereby lowering blood sugar levels [1] - The drug is intended for the treatment of type 2 diabetes and obesity [1]